Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1991 Oct;104(2):433–439. doi: 10.1111/j.1476-5381.1991.tb12447.x

Comparison of the electrophysiological effects of Org 7797, disopyramide, mexiletine and propafenone in anaesthetized dogs with myocardial infarcts.

J K Campbell 1, R J Marshall 1, E Winslow 1
PMCID: PMC1908530  PMID: 1797309

Abstract

1. The electrophysiological effects of intravenously administered Org 7797 were compared with those of disopyramide (class Ia), mexiletine (Ib) and propafenone (Ic) in anaesthetized dogs with 5-6 day-old left ventricular myocardial infarcts. 2. Org 7797 (0.5 mg kg-1) slowed conduction at all levels of the myocardium as shown by increases in St-A, AH, HV and QRS intervals, very modestly prolonged atrial and ventricular refractory periods and slightly shortened ventricular repolarization. Sinus node recovery time was increased whilst the RR interval was unchanged. A higher dose (2 mg kg-1) prolonged RR and rendered 5 out of 8 dogs unable to follow an atrial pacing stimulus of mean cycle length 322 ms. 3. Electrophysiological changes induced by propafenone (2 mg kg-1) were qualitatively similar to those of Org 7797 (0.5 mg kg-1). 4. Electrophysiological changes induced by mexiletine (2 mg kg-1) were small or insignificant. The most noticeable effect was a modest increase in the St-A interval and a slight shortening of ventricular repolarization. A higher dose (8 mg kg-1) additionally slowed conduction in the His-Purkinje system and in the ventricular myocardium. 5. Disopyramide (2 and 5 mg kg-1) prolonged all cardiac intervals including JTc, QTc and QT during pacing and prolonged cardiac refractory periods. 6. It was concluded that the electrophysiological profile of Org 7797 is more like that of the Ic agent propafenone than that of the class Ia and Ib drugs, disopyramide and mexiletine.

Full text

PDF
433

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alter W. A., 3rd, Hawkins R. N., Parkhurst L. J., Poulin S., Padgett D., Fink D. Barbiturate depression of neurally mediated reflexes to coronary artery occlusion. Proc Soc Exp Biol Med. 1979 Feb;160(2):281–286. doi: 10.3181/00379727-160-40435. [DOI] [PubMed] [Google Scholar]
  2. Bajaj A. K., Kopelman H. A., Wikswo J. P., Jr, Cassidy F., Woosley R. L., Roden D. M. Frequency- and orientation-dependent effects of mexiletine and quinidine on conduction in the intact dog heart. Circulation. 1987 May;75(5):1065–1073. doi: 10.1161/01.cir.75.5.1065. [DOI] [PubMed] [Google Scholar]
  3. Breithardt G., Borggrefe M., Wiebringhaus E., Seipel L. Effect of propafenone in the Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up. Am J Cardiol. 1984 Nov 14;54(9):29D–39D. doi: 10.1016/s0002-9149(84)80283-0. [DOI] [PubMed] [Google Scholar]
  4. Campbell T. J. Kinetics of onset of rate-dependent effects of Class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification. Cardiovasc Res. 1983 Jun;17(6):344–352. doi: 10.1093/cvr/17.6.344. [DOI] [PubMed] [Google Scholar]
  5. Connolly S. J., Kates R. E., Lebsack C. S., Echt D. S., Mason J. W., Winkle R. A. Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. Am J Cardiol. 1983 Dec 1;52(10):1208–1213. doi: 10.1016/0002-9149(83)90575-1. [DOI] [PubMed] [Google Scholar]
  6. Connolly S. J., Kates R. E., Lebsack C. S., Harrison D. C., Winkle R. A. Clinical pharmacology of propafenone. Circulation. 1983 Sep;68(3):589–596. doi: 10.1161/01.cir.68.3.589. [DOI] [PubMed] [Google Scholar]
  7. Costard-Jäckle A., Franz M. R. Frequency-dependent antiarrhythmic drug effects on postrepolarization refractoriness and ventricular conduction time in canine ventricular myocardium in vivo. J Pharmacol Exp Ther. 1989 Oct;251(1):39–46. [PubMed] [Google Scholar]
  8. Doherty J. U., Waxman H. L., Kienzle M. G., Cassidy D. M., Marchlinski F. E., Buxton A. E., Josephson M. E. Limited role of intravenous propafenone hydrochloride in the treatment of sustained ventricular tachycardia: electrophysiologic effects and results of programmed ventricular stimulation. J Am Coll Cardiol. 1984 Aug;4(2):378–381. doi: 10.1016/s0735-1097(84)80229-6. [DOI] [PubMed] [Google Scholar]
  9. Dreifus L. S. The electrophysiology of Norpace (Part I). Angiology. 1975 Jan;26(1 Pt 2):111–115. [PubMed] [Google Scholar]
  10. Giacomini J. C., Giacomini K. M., Nelson W. L., Harrison D. C., Blaschke T. F. Electrophysiology of the enantiomers of disopyramide in dogs. J Cardiovasc Pharmacol. 1985 Sep-Oct;7(5):884–890. doi: 10.1097/00005344-198509000-00011. [DOI] [PubMed] [Google Scholar]
  11. Guimond C., Vasseur C., Godin D., Pelletier B., LeBlanc A. R., Nadeau R. Intracardiac electrophysiological study of disopyramide in intact and chemically sympathectomized dogs. Eur Heart J. 1982 Dec;3(6):553–563. doi: 10.1093/oxfordjournals.eurheartj.a061352. [DOI] [PubMed] [Google Scholar]
  12. Hammill S. C., McLaran C. J., Wood D. L., Osborn M. J., Gersh B. J., Holmes D. R., Jr Double-blind study of intravenous propafenone for paroxysmal supraventricular reentrant tachycardia. J Am Coll Cardiol. 1987 Jun;9(6):1364–1368. doi: 10.1016/s0735-1097(87)80479-5. [DOI] [PubMed] [Google Scholar]
  13. Harrison D. C. Antiarrhythmic drug classification: new science and practical applications. Am J Cardiol. 1985 Jul 1;56(1):185–187. doi: 10.1016/0002-9149(85)90591-0. [DOI] [PubMed] [Google Scholar]
  14. Harron D. W., Brogden R. N. Propafenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias. Drugs. 1987 Dec;34(6):617–647. doi: 10.2165/00003495-198734060-00001. [DOI] [PubMed] [Google Scholar]
  15. Hashimoto K., Ishii M., Komori S. Antiarrhythmic plasma concentrations of mexiletine on canine ventricular arrhythmias. J Cardiovasc Pharmacol. 1984 Mar-Apr;6(2):213–219. doi: 10.1097/00005344-198403000-00001. [DOI] [PubMed] [Google Scholar]
  16. Hashimoto K., Satoh H., Shibuya T., Imai S. Canine-effective plasma concentrations of antiarrhythmic drugs on the two-stage coronary ligation arrhythmia. J Pharmacol Exp Ther. 1982 Dec;223(3):801–810. [PubMed] [Google Scholar]
  17. Janse M. J., Wilms-Schopman F., Opthof T. Mechanism of antifibrillatory action of Org 7797 in regionally ischemic pig heart. J Cardiovasc Pharmacol. 1990 Apr;15(4):633–643. doi: 10.1097/00005344-199004000-00017. [DOI] [PubMed] [Google Scholar]
  18. Karagueuzian H. S., Katoh T., McCullen A., Mandel W. J., Peter T. Electrophysiologic and hemodynamic effects of propafenone, a new antiarrhythmic agent, on the anesthetized, closed-chest dog: comparative study with lidocaine. Am Heart J. 1984 Mar;107(3):418–424. doi: 10.1016/0002-8703(84)90080-2. [DOI] [PubMed] [Google Scholar]
  19. Kidwell G. A., Lima J. J., Schaal S. F., Muir W. W., 3rd Hemodynamic and electrophysiologic effects of disopyramide enantiomers in a canine blood superfusion model. J Cardiovasc Pharmacol. 1989 Apr;13(4):644–655. [PubMed] [Google Scholar]
  20. Kirchhof C., Wijffels M., Brugada J., Planellas J., Allessie M. Mode of action of a new class IC drug (ORG 7797) against atrial fibrillation in conscious dogs. J Cardiovasc Pharmacol. 1991 Jan;17(1):116–124. doi: 10.1097/00005344-199101000-00017. [DOI] [PubMed] [Google Scholar]
  21. Kreeger R. W., Hammill S. C. New antiarrhythmic drugs: tocainide, mexiletine, flecainide, encainide, and amiodarone. Mayo Clin Proc. 1987 Nov;62(11):1033–1050. doi: 10.1016/s0025-6196(12)65077-0. [DOI] [PubMed] [Google Scholar]
  22. Lee J. T., Davy J. M., Kates R. E. Evaluation of combined administration of verapamil and disopyramide in dogs. J Cardiovasc Pharmacol. 1985 May-Jun;7(3):501–507. doi: 10.1097/00005344-198505000-00014. [DOI] [PubMed] [Google Scholar]
  23. Marrott P. K., Ruttley M. S., Winterbottam J. T., Muir J. R. A study of the acute electrophysiological and cardiovascular action of disopyramide in man. Eur J Cardiol. 1976 Sep;4(3):303–312. [PubMed] [Google Scholar]
  24. Marshall R. J., Parratt J. R. The effects of disopyramide phosphate on early post-coronary artery ligation dysrhythmias and on epicardial ST-segment elevation in anaesthetized dogs. Br J Pharmacol. 1979 Jun;66(2):241–250. doi: 10.1111/j.1476-5381.1979.tb13672.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Mirro M. J., Manalan A. S., Bailey J. C., Watanabe A. M. Anticholinergic effects of disopyramide and quinidine on guinea pig myocardium. Mediation by direct muscarinic receptor blockade. Circ Res. 1980 Dec;47(6):855–865. doi: 10.1161/01.res.47.6.855. [DOI] [PubMed] [Google Scholar]
  26. Nestico P. F., Morganroth J., Horowitz L. N. New antiarrhythmic drugs. Drugs. 1988 Mar;35(3):286–319. doi: 10.2165/00003495-198835030-00005. [DOI] [PubMed] [Google Scholar]
  27. Ross D., Vohra J., Sloman J. G. Disopyramide in myocardial infarction. Lancet. 1978 Feb 11;1(8059):330–330. doi: 10.1016/s0140-6736(78)90103-4. [DOI] [PubMed] [Google Scholar]
  28. Seipel L. Electrophysiologic effects of propafenone. Am Heart J. 1984 Dec;108(6):1587–1588. doi: 10.1016/0002-8703(84)90728-2. [DOI] [PubMed] [Google Scholar]
  29. Shen E. N., Sung R. J., Morady F., Schwartz A. B., Scheinman M. M., DiCarlo L., Shapiro W. Electrophysiologic and hemodynamic effects of intravenous propafenone in patients with recurrent ventricular tachycardia. J Am Coll Cardiol. 1984 May;3(5):1291–1297. doi: 10.1016/s0735-1097(84)80190-4. [DOI] [PubMed] [Google Scholar]
  30. Waleffe A., Mary-Rabine L., de Rijbel R., Soyeur D., Legrand V., Kulbertus H. E. Electrophysiological effects of propafenone studied with programmed electrical stimulation of the heart in patients with recurrent paroxysmal supraventricular tachycardia. Eur Heart J. 1981 Aug;2(4):345–352. doi: 10.1093/oxfordjournals.eurheartj.a061215. [DOI] [PubMed] [Google Scholar]
  31. Winslow E., Martorana M., Bell P. Electrophysiologic effects of Org 7797, a new steroidal antiarrhythmic agent: comparison with class 1a, 1b, and 1c drugs. J Cardiovasc Pharmacol. 1989 Aug;14(2):205–212. doi: 10.1097/00005344-198908000-00004. [DOI] [PubMed] [Google Scholar]
  32. Yoon M. S., Han J. Electrophysiologic effects of mexiletine on normal and ischemic ventricles. J Electrocardiol. 1982 Apr;15(2):109–113. doi: 10.1016/s0022-0736(82)80002-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES